secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2024-05-31T23:59:59+00:00
Accession:  0001193125-24-151007
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interim CEO departs, CFO takes PEO role, new CCO, FDA immunobridging path
-------------------------------------------------------------------------

- Jeremy Gowler ceases as interim CEO, COO, CCO effective May 30; employment ends June 29.
- CFO William Duke Jr. appointed principal executive officer; continues as CFO and principal accounting officer.
- Timothy Lee appointed Chief Commercial Officer; previously led Amylyx sales ($390M revenue in 14 months).
- FDA alignment on repeatable immunobridging pathway for serial mAbs COVID-19 EUAs; Est. clinical cost $25-40M per mAb.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312524151007/0001193125-24-151007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312524151007/d831636d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-151007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer